Product Code: RA100140
The cell and gene therapy supply chain software market is valued at USD 274 billion in 2024 growing at a CAGR of 15.2% during the forecast period 2024-2035.
Pioneering cell and gene therapies have catalyzed a paradigm shift in healthcare delivery, revolutionizing the development, production, and consumption of cutting-edge medicine. These groundbreaking therapeutics have empowered healthcare professionals to combat rare clinical conditions that once seemed insurmountable. Over the past few decades, more than 30 such transformative modalities have garnered regulatory approval, with recent triumphs including ELEVIDYS(R) (2023), Adstiladrin(R) (2022), Breyanzi(R) (2022), CARVYKTI(R) (2022), Abecma(R) (2021), Allocord(TM) (2019), LUXTURNA(TM) (2017), and Yescarta(R) (2017). Moreover, a report by Novotech heralded the anticipated approval of more than 12 novel cell and gene therapies by the end of 2023, underscoring lucrative prospects for stakeholders in this burgeoning domain. Notably, post-2018, over 40% of clinical trials addressing rare diseases involved the evaluation of innovative cell and gene therapy products. Based on the current pipeline and historical clinical success rates, projections indicate that the United States Food and Drug Administration could approve 10-20 advanced therapies annually until 2025. Consequently, the demand for innovative software solutions to streamline supply chain management is poised to surge, presenting growth opportunities for cell and gene therapy software providers.
Importantly, the commercial triumph of cell and gene therapy products hinges not only on their therapeutic efficacy but also on developers' ability to seamlessly navigate complex supply chain intricacies. The cell and gene therapy supply chain is inherently more intricate than conventional pharmaceutical supply chains due to the temperature sensitivity and uniqueness of these products. Consequently, therapy developers must grapple with an array of risks, including operational inefficiencies, capacity scheduling challenges, process delays leading to capital losses, and delivery/tracking-related issues. This intricate landscape has fueled the need for tailored software solutions that can seamlessly integrate with existing processes, empowering drug developers to oversee and manage every aspect of the cell and gene therapy supply chain at each juncture. Over time, numerous innovative software solutions have emerged, offering supply chain orchestration and needle-to-needle traceability capabilities. The market has witnessed a surge in partnerships aimed at advancing these software solutions. Furthermore, driven by the growing demand for cost-effective personalized medicinal products and the cost-saving potential of implementing such software solutions, the cell and gene therapy supply chain software market is poised for substantial growth.
Key Market Segments
Process Component
- Sample Collection and Processing Component
- Manufacturing Component
- Logistics Component
- Patient Identification and Treatment Follow-up Component
Type of Software
- Enterprise Manufacturing System (EMS)
- Laboratory Information Management System (LIMS)
- Inventory Management System (IMS)
- Cell Orchestration Platform (COP)
- Quality Management System (QMS)
- Logistics Management System (LMS)
- Patient Management System (PMS)
Mode of Deployment
- On-premises Deployment
- Cloud-based Deployment
Type of End-User
- Pharmaceutical Companies
- Cell Therapy Labs
- Hospitals / Medical Centers
- Research Institutes / Biobanks
Type of End-User
- Clinical Scale
- Commercial Scale
Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
Research Coverage:
- The report studies the cell and gene therapy supply chain software market based on process component, type of software, mode of deployment, type of end-user, scale of operation and key geographical regions.
- The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
- The report forecasts the revenue of market segments with respect to four major regions
- The report begins with a general overview of the cell and gene therapy supply chain, highlighting different types of software solutions, their key features, and applications. It also covers the advantages of supply chain software in this industry, challenges with conventional supply chains, and opportunities and future perspectives associated with supply chain management software.
- It provides a detailed overview of the current market landscape for cell and gene therapy supply chain software solutions, based on parameters such as software type (cell orchestration platform, enterprise manufacturing system, inventory management system, laboratory information management system, logistics management system, patient management system, quality management system, and tracking and tracing system), key features (compatibility/integration, traceability, data analytics/visualization, scalability, user-friendliness, chain of identity/custody), application area, mode of deployment, scale of operation, regulatory guidelines followed, and end-user type. Additionally, it lists developers offering these solutions, analyzing them based on establishment year, company size, headquarters location, and active players.
- The report offers an insightful competitiveness analysis of companies in this market, based on developer strength (experience, company size) and product portfolio strength (partnerships, application areas, features, end-users, deployment mode, operation scale, regulatory guidelines).
- It includes elaborate profiles of key software providers, featuring company overviews, software portfolios, financial information, recent developments, and future outlooks.
- The report provides an in-depth analysis of funding and investments in this domain since 2014, including seed funding, venture capital, debt financing, grants/awards, IPO proceeds, and subsequent offerings received by companies operating in this market.
- It presents a detailed analysis of partnerships, including acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements, and others, inked between companies in this market since 2019.
- The report offers an in-depth analysis of platform utilization agreements signed since 2019, providing information on different software types utilized by end-users in the cell and gene therapy supply chain.
- It includes a qualitative assessment of current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers, regulators/payers) involved in the cell and gene therapy supply chain, highlighting the diverse needs and their impact on the supply chain and industry preparedness.
- The report provides an in-depth analysis of factors impacting the growth of this market, including key drivers, potential restraints, emerging opportunities, and existing challenges.
- It offers a detailed estimate of the current market size and future growth potential of the cell and gene therapy supply chain software market until 2035, based on likely adoption trends and reliable secondary and primary validations. The report features three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.
- The report includes detailed projections of the current and future market opportunity across various process components (sample collection/processing, manufacturing, logistics, patient identification/treatment follow-up), software types, deployment modes, operation scales, end-user types, and key geographical regions.
Key Benefits of Buying this Report
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the cell and gene therapy supply chain software market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Key Market Companies
- Azenta Life Sciences
- Biocair
- BioLife Solutions
- CareDx
- Cryoport
- Lonza
- NMDP BioTherapies
- TraceLink
- TrakCel
- Veeva Systems
- Emerson
- LabVantage Solutions
- Marken
- MasterControl
- QuickSTAT
- Siemens
- Stafa Cellular Therapy
- Steiner
- STEMSOFT Software
TECHNIDATA
TABLE OF CONTENTS
1. PREFACE
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current and Future Estimates
- 3.2.2. Currency Coverage and Foreign Exchange Rate
- 3.2.2.1. Major Currencies Affecting the Market
- 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
- 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
- 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
- 3.2.3. Trade Policies
- 3.2.3.1. Impact of Trade Barriers on the Market
- 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
- 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
- 5.1. Chapter Overview
- 5.2. Overview of Cell Therapies
- 5.3. Advanced Therapy Medicinal Products (ATMPs)
- 5.3.1. Difference between Cell / Advanced Therapies and Other Biotechnology Products
- 5.4. Overview of Cell and Gene Therapy Supply Chain
- 5.4.1. Software Solutions for Cell and Gene Therapy Supply Chain
- 5.4.1.1. Enterprise Manufacturing System (EMS)
- 5.4.1.2. Laboratory Information Management System (LIMS)
- 5.4.1.3. Inventory Management System (IMS)
- 5.4.1.4. Quality Management System (QMS)
- 5.4.1.5. Logistics Management System (LMS)
- 5.4.1.6. Patient Management System (PMS)
- 5.4.1.7. Cell Orchestration Platform (COP)
- 5.4.2. Challenges in Cell and Advanced Therapy Supply Chain
- 5.5. Recent Developments and Future Outlook
6. MARKET LANDSCAPE
- 6.1. Chapter Overview
- 6.2. Cell and Gene Therapy Supply Chain Software: Overall Market Landscape
- 6.2.1. Analysis by Type of Software
- 6.2.2. Analysis by Key Features
- 6.2.3. Analysis by Application Area
- 6.2.4. Analysis by Mode of Deployment
- 6.2.5. Analysis by Type of Software and Mode of Deployment
- 6.2.6. Analysis by Scale of Operation
- 6.2.7. Analysis by Type of Software and Scale of Operation
- 6.2.8. Analysis by Regulatory Guidelines Followed
- 6.2.9. Analysis by Type of End-User
- 6.2.10. Analysis by Type of Software and End-User
- 6.3. Cell and Gene Therapy Supply Chain Software: Developer Landscape
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Year of Establishment and Company Size
- 6.3.4. Analysis by Location of Headquarters
- 6.3.5. Analysis by Number of Software Solutions Offered
- 6.3.6. Most Active Players: Analysis by Number of Software Solutions Offered
7. COMPANY COMPETITIVENESS ANALYSIS
- 7.1. Chapter Overview
- 7.2. Assumptions and Key Parameters
- 7.3. Methodology
- 7.4. Company Competitiveness Analysis: Cell and Gene Therapy Supply Chain Software Providers
- 7.4.1 COP Developers
- 7.4.2. EMS Developers
- 7.4.3. IMS Developers
- 7.4.4. LIMS Developers
- 7.4.5. LMS Developers
- 7.4.6. PMS Developers
- 7.4.7. QMS Developers
- 7.4.8. TTS Developers
8. COMPANY PROFILES
- 8.1. Chapter Overview
- 8.2. Leading Players in Cell and Gene Therapy Supply Chain Software Market
- 8.2.1. Azenta Life Sciences
- 8.2.1.1. Company Overview
- 8.2.1.2. Supply Chain Management Solutions Portfolio
- 8.2.1.3. Financial Information
- 8.2.1.4. Recent Developments and Future Outlook
- 8.2.2. NMDP BioTherapies
- 8.2.2.1. Company Overview
- 8.2.2.2. Supply Chain Management Solutions Portfolio
- 8.2.2.3. Financial Information
- 8.2.2.4. Recent Developments and Future Outlook
- 8.2.3. Biocair
- 8.2.3.1. Company Overview
- 8.2.3.2. Supply Chain Management Solutions Portfolio
- 8.2.3.3. Recent Developments and Future Outlook
- 8.2.4. BioLife Solutions
- 8.2.4.1. Company Overview
- 8.2.4.2. Supply Chain Management Solutions Portfolio
- 8.2.4.3. Financial Information
- 8.2.4.4. Recent Developments and Future Outlook
- 8.2.5. CareDx
- 8.2.5.1. Company Overview
- 8.2.5.2. Supply Chain Management Solutions Portfolio
- 8.2.5.3. Financial Information
- 8.2.5.4. Recent Developments and Future Outlook
- 8.2.6. Cryoport
- 8.2.6.1. Company Overview
- 8.2.6.2. Supply Chain Management Solutions Portfolio
- 8.2.6.3. Financial Information
- 8.2.6.4. Recent Developments and Future Outlook
- 8.2.7. Lonza
- 8.2.7.1. Company Overview
- 8.2.7.2. Supply Chain Management Solutions Portfolio
- 8.2.7.3. Financial Information
- 8.2.7.3. Recent Developments and Future Outlook
- 8.2.8. TraceLink
- 8.2.8.1. Company Overview
- 8.2.8.2. Supply Chain Management Solutions Portfolio
- 8.2.8.4. Recent Developments and Future Outlook
- 8.2.9. TrakCel
- 8.2.9.1. Company Overview
- 8.2.9.2. Supply Chain Management Solutions Portfolio
- 8.2.9.3. Recent Developments and Future Outlook
- 8.2.10. Veeva Systems
- 8.2.10.1. Company Overview
- 8.2.10.2. Supply Chain Management Solutions Portfolio
- 8.2.10.3. Financial Information
- 8.2.10.4. Recent Developments and Future Outlook
- 8.3. Other Leading Players in Cell and Gene Therapy Supply Chain Software Market
- 8.3.1. Emerson
- 8.3.1.1. Company Overview
- 8.3.1.2. Supply Chain Management Solutions Portfolio
- 8.3.2. LabVantage Solutions
- 8.3.2.1. Company Overview
- 8.3.2.2. Supply Chain Management Solutions Portfolio
- 8.3.3. Marken
- 8.3.3.1. Company Overview
- 8.3.3.2. Supply Chain Management Solutions Portfolio
- 8.3.4. MasterControl
- 8.3.4.1. Company Overview
- 8.3.4.2. Supply Chain Management Solutions Portfolio
- 8.3.5. QuickSTAT
- 8.3.5.1. Company Overview
- 8.3.5.2. Supply Chain Management Solutions Portfolio
- 8.3.6. Siemens
- 8.3.6.1. Company Overview
- 8.3.6.2. Supply Chain Management Solutions Portfolio
- 8.3.7. Stafa Cellular Therapy
- 8.3.7.1. Company Overview
- 8.3.7.2. Supply Chain Management Solutions Portfolio
- 8.3.8. Steiner
- 8.3.8.1. Company Overview
- 8.3.8.2. Supply Chain Management Solutions Portfolio
- 8.3.9. STEMSOFT Software
- 8.3.9.1. Company Overview
- 8.3.9.2. Supply Chain Management Solutions Portfolio
- 8.3.10. TECHNIDATA
- 8.3.10.1. Company Overview
- 8.3.10.2. Supply Chain Management Solutions Portfolio
- 8.3.11. Thermo Fisher Scientific
- 8.3.11.1. Company Overview
- 8.3.11.2. Supply Chain Management Solutions Portfolio
9. FUNDING AND INVESTMENT ANALYSIS
- 9.1. Chapter Overview
- 9.2. Funding Models
- 9.3. Cell and Gene Therapy Supply Chain Software: Funding and Investment Analysis
- 9.3.1. Analysis by Year of Funding
- 9.3.2. Analysis by Amount Invested
- 9.3.3. Analysis by Type of Funding
- 9.3.4. Analysis by Type of Funding and Amount Invested
- 9.3.5. Analysis of Amount Invested by Year and Type of Funding
- 9.3.6. Analysis by Geography
- 9.3.7. Most Active Players: Analysis by Number of Instances
- 9.3.8. Most Active Players: Analysis by Amount Raised
- 9.3.9. Key Investors: Analysis by Number of Funding Instances
- 9.3.10. Analysis by Type of Investor
- 9.5. Concluding Remarks
10. PARTNERSHIPS AND COLLABORATIONS
- 10.1. Chapter Overview
- 10.2. Partnership Models
- 10.3. Cell and Gene Therapy Supply Chain Software: Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Type of Partnership and Company Size
- 10.3.5. Analysis by Type of Partner
- 10.3.6. Analysis by Type of Software Involved
- 10.3.7. Most Active Players: Analysis by Number of Partnerships
- 10.3.8. Analysis by Geography
- 10.3.8.1. Local and International Agreements
- 10.3.8.2. Intracontinental and Intercontinental Agreements
11. PLATFORM UTILIZATION AGREEMENTS IN SUPPLY CHAIN SOFTWARE SOLUTIONS MARKET
- 11.1. Chapter Overview
- 11.2. Platform Utilization Agreements in Supply Chain Software Solutions Market: List of Agreements
- 11.2.1. Analysis by Year of Agreement
- 11.2.2. Analysis by Type of Partner
- 11.2.3. Analysis by Type of Software Involved
- 11.2.4. Analysis by Type of Partner and Type of Software Involved
- 11.2.5. Analysis of Partners by Geography
- 11.2.5. Most Active Players: Analysis by Number of Platform Utilization Agreements
12. STAKEHOLDER NEEDS ANALYSIS
- 12.1. Chapter Overview
- 12.2. Cell and Gene Therapy Supply Chain: Needs of Different Stakeholders
- 12.2.1. Comparison of Stakeholder Needs
- 12.2.2. Conclusion
13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
- 13.1. Chapter Overview
- 13.2. Market Drivers
- 13.3. Market Restraints
- 13.4. Market Opportunities
- 13.5. Market Challenges
- 13.6. Conclusion
14. GLOBAL CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET
- 14.1. Chapter Overview
- 14.2. Assumptions and Methodology
- 14.3. Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 14.3.1. Scenario Analysis
- 14.3.1.1. Conservative Scenario
- 14.3.1.2. Optimistic Scenario
- 14.4. Key Market Segmentations
- 14.5. Dynamic Dashboard
15. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY PROCESS COMPONENT
- 15.1. Chapter Overview
- 15.2. Key Assumptions and Methodology
- 15.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035
- 15.3.1. Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
- 15.3.2. Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 15.3.3. Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 15.3.4. Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 15.4. Data Triangulation and Validation
16. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF SOFTWARE
- 16.1. Chapter Overview
- 16.2. Key Assumptions and Methodology
- 16.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035
- 16.3.1. Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.3.2. Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.3.3. Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.3.4. Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.3.5. Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.3.6. Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.3.7. Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 16.4. Data Triangulation and Validation
17. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY MODE OF DEPLOYMENT
- 17.1. Chapter Overview
- 17.2. Key Assumptions and Methodology
- 17.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035
- 17.3.1. Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 17.3.2. Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 17.4. Data Triangulation and Validation
18. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY SCALE OF OPERATION
- 18.1. Chapter Overview
- 18.2. Key Assumptions and Methodology
- 18.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035
- 18.3.1. Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 18.3.2. Cell and Gene Therapy Supply Chain Software Market for Commercial Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 18.4. Data Triangulation and Validation
19. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF END-USER
- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035
- 19.3.1. Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 19.3.2. Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 19.3.3. Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 19.3.4. Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 19.4. Data Triangulation and Validation
20. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY KEY GEOGRAPHICAL REGIONS
- 20.1. Chapter Overview
- 20.2. Key Assumptions and Methodology
- 20.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
- 20.3.1. Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.1.1. Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.1.2. Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2. Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2.1. Cell and Gene Therapy Supply Chain Software Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2.2. Cell and Gene Therapy Supply Chain Software Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2.3. Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2.4. Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2.5. Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.2.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3. Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3.1. Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3.2. Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3.3. Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3.4. Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3.5. Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.3.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.4. Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.4.1. Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.4.2. Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.4.3. Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.3.4.4. Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
- 20.4. Data Triangulation and Validation
21. CONCLUSION
22. EXECUTIVE INSIGHTS
- 22.1. Chapter Overview
- 22.2. TrakCel
- 22.2.1. Company Snapshot
- 22.2.2. Interview Transcript: Martin Lamb, (Former Chief Business Officer)
- 22.3. Cell and Gene Therapy Catapult
- 22.3.1. Company Snapshot
- 22.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
- 22.4. McKesson
- 22.4.1. Company Snapshot
- 22.4.2. Interview Transcript: Divya Iyer, Former Senior Director, Corporate Strategy and Business Development
- 22.5. Inlog
- 22.5.1. Company Snapshot
- 22.5.2. Interview Transcript: David Delay, International Sales and Transfusion Manager
- 22.6. Thermo Fisher Scientific
- 22.6.1. Company Snapshot
- 22.6.2. Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy
23. APPENDIX 1: TABULATED DATA
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS